Pyxis Oncology Prices $110M Raise for MICVO's Phase 3

Pyxis Oncology has priced an underwritten public offering of common stock, pre-funded warrants and accompanying warrants, raising roughly $110 million in gross proceeds to carry its lead antibody-drug conjugate, MICVO, toward a planned Phase 3 trial in head and neck cancer. The Nasdaq-listed company, trading as PYXS, priced the offering on 30 September 2026 and closed it on 1 October; if every warrant is exercised for cash, the deal can raise as much as $282.6 million in total.

Head and neck cancer's crowded late line

Patients with recurrent or metastatic head and neck squamous cell carcinoma who progress after platinum-based chemotherapy and a checkpoint inhibitor have few options built specifically for that setting: Pyxis Oncology is trying to build one. The company's own planned Phase 3 trial names the field it has to beat directly — cetuximab, docetaxel or methotrexate, the three standard investigator's-choice regimens an oncologist reaches for today.

The offering, in four figures

$110Mgross proceeds from shares and pre-funded warrants

$282.6Mtotal potential gross proceeds if every warrant is exercised for cash

36%confirmed objective response rate in a 33-patient Phase 1 update, 9 September 2026

~500patients planned for Headliner, the Phase 3 trial the raise is meant to fund

Figures from Pyxis Oncology's SEC filings and its 9 September 2026 clinical data update.

A target outside the cell, not on it

Most approved antibody-drug conjugates bind a receptor on the surface of the tumor cell itself. MICVO instead targets extradomain-B of fibronectin, a protein Pyxis says is expressed in the extracellular matrix — the structural scaffolding around a tumor, not the cell — which the company calls an early-in-concept approach among ADCs. Pyxis describes MICVO working three ways at once: direct cytotoxic killing, a bystander effect that reaches neighboring tumor cells regardless of whether they carry the target, and immunogenic cell death, which the company says may also support benefit when paired with a checkpoint inhibitor like pembrolizumab in earlier treatment lines.

Three things MICVO is betting on

01

A target outside the cell

MICVO binds a structural protein in the tumor's extracellular matrix rather than a cell-surface receptor, a mechanism Pyxis positions as applicable across a broader range of solid tumors than a single-receptor ADC.

02

Three ways to kill the tumor

Pyxis describes direct cytotoxicity, a bystander effect on neighboring cells, and immunogenic cell death as three distinct mechanisms layered into one molecule, with potential added benefit in combination with anti-PD-1 therapy.

03

Fast Track, ahead of Phase 3

FDA has already granted MICVO Fast Track Designation for second-line-and-beyond recurrent or metastatic head and neck cancer patients who progressed on platinum chemotherapy and anti-PD-(L)1 therapy, ahead of the Phase 3 trial this offering is meant to fund.

What $110 million is meant to buy

The capital arrives nine days after Pyxis reported an updated Phase 1 readout: a 36% confirmed objective response rate and 94% disease control rate among 33 efficacy-evaluable patients at the 5.4 mg/kg dose the company has selected to carry into Phase 3, with a median progression-free survival of 6.2 months. Pyxis says the proceeds from this offering, together with its existing cash, will carry MICVO through the steps ahead of Headliner — including a planned early-2027 meeting with FDA to align on the trial's dose — rather than fund the roughly 500-patient trial to completion on its own.

“The second quarter was marked by continued execution across the MICVO program and a financing that strengthened our balance sheet and extended our cash runway into the second quarter of 2027. The additional capital gives us greater flexibility to incorporate longer patient follow-up and planned analyses into our next clinical updates.” Thomas Civik, Chief Executive Officer, Pyxis Oncology — August 2026, discussing an earlier financing ahead of this offering

The ADC market MICVO is funded to enter

Antibody-drug conjugates have become one of oncology's most actively invested categories, propelled in part by large acquisitions — Pfizer's $43 billion purchase of Seagen and AbbVie's $10.1 billion purchase of ImmunoGen among them. MICVO would enter that category without a receptor-based mechanism to differentiate it from the crowd the usual way; its case instead rests on the extracellular-matrix target and its showing so far in head and neck cancer specifically.

The ADC market MICVO is funded to enter

$20.12B → $71.55B

Global antibody-drug conjugate (ADC) market, 2026 to 2031, as forecast by Mordor Intelligence.

2025$15.61B

2026$20.12B

2031$71.55B

Sources: Mordor Intelligence, Antibody Drug Conjugates Market Size and Share report

Regulatory News outlook

We expect MICVO's path to depend less on the overall ADC category's growth than on differentiation within an already crowded head and neck cancer late line — the same three comparator regimens, cetuximab, docetaxel and methotrexate, that Pyxis has already built into its own planned Phase 3 trial design.

How we got here: Mordor Intelligence's published 28.88% compound annual growth rate for 2026-2031 applied to its own $20.12 billion 2026 ADC-market estimate reaches its own $71.55 billion 2031 figure; we treat category-wide ADC growth as necessary but not sufficient for MICVO specifically, given the named late-line comparators its trial has to beat.

MICVO against the late-line field it must beat

Product	Mechanism	Status in 2L+ R/M HNSCC	US regulatory status
MICVO (Pyxis Oncology)	ADC targeting extradomain-B of fibronectin (extracellular matrix)	Phase 1 monotherapy and combination trials; Phase 3 (Headliner) planned	FDA Fast Track Designation; not approved
Pembrolizumab (Merck, Keytruda)	PD-1 checkpoint inhibitor	Approved second-line-and-beyond since 2016; later expanded to first-line	FDA approved, marketed
Cetuximab (Erbitux)	Anti-EGFR monoclonal antibody	One of three investigator's-choice comparator arms in Pyxis's own Headliner design	FDA approved, long-marketed
Trastuzumab deruxtecan (Daiichi Sankyo/AstraZeneca, Enhertu)	HER2-targeting ADC	Investigational in HER2-positive head and neck and salivary gland cancer	FDA approved in other cancers, not in HNSCC

From each company's own labelling, FDA records and Pyxis's own announced trial design; not a clinical comparison.

From a 2019 launch to a Nasdaq raise

MICVO's road to a Phase 3 design

1. July 2019

   Pyxis Oncology launched

   Publicly launched by the Longwood Fund with Thomas Gajewski, M.D., Ph.D. and John Flavin, backed by a $22 million Series A led by Leaps by Bayer.

2. 8 October 2021

   Nasdaq IPO

   Shares begin trading on the Nasdaq Global Select Market as PYXS, in an upsized $168 million initial public offering priced at $16.00 a share.

3. November 2024

   First MICVO data

   Pyxis reports preliminary Phase 1 results in recurrent or metastatic head and neck cancer; the stock falls sharply as analysts question the drug's differentiation in a crowded field.

4. 2 July 2026

   Private placement closes

   A roughly $50 million private placement closes, led by BVF Partners, extending the company's stated cash runway into the second quarter of 2027.

5. 4 September 2026

   Civik named permanent CEO

   Thomas Civik, interim CEO since February, is named CEO and Chairman of the Board; co-founder John Flavin moves from Founding Chairman to Lead Independent Director.

6. 9 September 2026

   Updated Phase 1 data

   Pyxis reports a 36% confirmed objective response rate and 94% disease control rate among 33 evaluable patients, at the dose selected for Phase 3.

7. 1 October 2026

   Public offering closes

   The underwritten public offering closes, with gross proceeds of roughly $110 million and the potential for up to $282.6 million if every warrant is exercised.

8. Q1 2027 (planned)

   FDA dose-alignment meeting

   Pyxis says it plans to meet with FDA to align on Headliner's dose before the Phase 3 trial begins.

What this offering does not resolve: Headliner has not yet started, its FDA dose-alignment meeting is not until the first quarter of 2027, and Pyxis has not disclosed a specific trial-start date. The Phase 1 data behind this raise is drawn from a still-small efficacy-evaluable population, and the company's own update added only a modest number of new monotherapy patients since its November 2024 readout — the kind of gap a randomized Phase 3 trial is designed to settle.

• The raise: 36,047,919 shares (or pre-funded warrants) plus accompanying warrants, priced at $2.90 combined, for roughly $110 million gross and up to $282.6 million with full warrant exercise.
• The data behind it: a 36% confirmed objective response rate and 94% disease control rate among 33 evaluable Phase 1 monotherapy patients, reported 9 September 2026.
• The regulatory status: FDA Fast Track Designation for MICVO in 2L+ recurrent/metastatic head and neck cancer; no approval, clearance or Breakthrough Therapy Designation has been reported.
• Not yet public: a confirmed start date for the Headliner Phase 3 trial, which Pyxis says will follow a planned early-2027 FDA meeting on dose selection.

Frequently asked questions

What is the $110 million for?

Pyxis Oncology says the proceeds will advance MICVO (micvotabart pelidotin) through upcoming clinical milestones, including Headliner, its planned Phase 3 trial in second-line-and-beyond recurrent or metastatic head and neck cancer, plus working capital and general corporate purposes. The offering can raise up to $282.6 million in total if all accompanying and pre-funded warrants are exercised for cash.

Is this Pyxis's only financing this year?

No. Pyxis closed a roughly $50 million private placement on 2 July 2026, led by BVF Partners, and separately registered 39.2 million shares for resale by existing selling stockholders on 20 August 2026 — a resale filing that raises no new capital for the company and is a distinct transaction from this public offering.

What is MICVO, and what does it target?

MICVO (micvotabart pelidotin) is an antibody-drug conjugate that targets extradomain-B of fibronectin, a structural component of the extracellular matrix in and around a tumor, rather than a receptor on the tumor cell's surface. Pyxis describes a three-part mechanism: direct cytotoxicity, a bystander effect on neighboring tumor cells, and immunogenic cell death.

Has FDA approved MICVO?

No. MICVO holds FDA Fast Track Designation and is still in Phase 1 monotherapy and combination-therapy trials. Pyxis's planned Phase 3 trial, Headliner, has not yet begun; the company says it plans to meet with FDA to align on the trial's dose in the first quarter of 2027.